{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(1)"],"submitter":["Hidalgo-Tenorio C"],"pubmed_abstract":["OBJECTIVES:To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. METHODS:A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. RESULTS:Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49"],"journal":["Annals of clinical microbiology and antimicrobials"],"pagination":["30"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6800500"],"repository":["biostudies-literature"],"pubmed_title":["DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci."],"pmcid":["PMC6800500"],"pubmed_authors":["Herrero C","Sequera S","Iftimie S","Bereciartua E","Munoz P","Miro JM","De Jesus SE","Fernandez-Roldan C","Vinuesa D","Farinas MC","Martinez-Marcos FJ","Hidalgo-Tenorio C","Martin Davila P","Loeches B","Lopez-Cortes LE","Pasquau J","Plata A","Javier-Martinez R","Arenas-Miras MDM"],"additional_accession":[]},"is_claimable":false,"name":"DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.","description":"OBJECTIVES:To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. METHODS:A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. RESULTS:Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Oct","modification":"2025-04-22T21:31:50.475Z","creation":"2019-11-05T08:03:54Z"},"accession":"S-EPMC6800500","cross_references":{"pubmed":["31629409"],"doi":["10.1186/s12941-019-0329-6"]}}